Critics said today’s announcement is more evidence of the current administration’s willingness to undermine public trust in vaccines.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
One study describes an increase in US hospital deaths during a surge, 1 notes a rise in the risk of dying at home, and 1 notes decreased hospital deaths in New York City.
The prevalence of Clostridioides difficile infection (CDI) in the United States declined during the COVID-19 pandemic, but inpatient mortality and treatment costs were higher, according to a paper published yesterday in Open Forum Infectious Diseases.
The drugs reduced disease progression, hospitalization, and death in people 65 and older.
Central line-associated bloodstream infections, ventilator-associated events, and C difficile infections all increased.
At a World Health Organization (WHO) briefing today, Director-General Tedros Adhanom Ghebreyesus, PhD, said COVID-19 deaths for 2022 alone passed 1 million this week, as he pressed countries to do more to vaccinate all healthcare workers, older people, and others at highest risk. Since the pandemic began in early 2020, 6,472,848 deaths have been reported, according to the Johns Hopkins online dashboard.
Whether the increase was caused by COVID-19 or other factors remains unclear.
In other developments, global COVID-19 cases and deaths declined again last week.
In 2020, amid the COVID-19 pandemic, life expectancy in the United States fell by 4.5 and 3.6 years for Hispanic and Black males, respectively, while declining 1.5 years for their White counterparts, finds a study published yesterday in PNAS.
At least 2.5 hours of moderate activity or 1.2 hours of vigorous exercise weekly was linked to lower risk.
In another development, Pfizer said the vaccine for younger kids still shows strong efficacy as it prepares to file an EUA for a BA.5/BA.4 bivalent booster for kids as young as 6 months.